Nicox will participate in financial and scientific events in Q3 2022

Nicox will participate in financial and scientific events in Q3 2022

Facebook
Twitter
LinkedIn

press release Nicox will participate in financial and scientific events in Q3 2022 August 3, 2022 – Release at 7:30am BST
Sophia Antipolis, France

Nicox S.A FR COX))), an international eye care company, announced that members of its executive team will be attending the following financial and scientific conferences in Europe and the US in the coming months:

financial conferences

Nicox Chief Executive Officer Andreas Segerros will present at these conferences. Members of the Management Team are available for one-on-one meetings.

Scientific Conferences

Nicox Chief Scientific Officer Doug Hubatsch will be speaking at the event.
Members of the leadership team, including Andreas Segerros, Chief Executive Officer, will be present and available for one-on-one meetings. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to preserve vision and improve eye health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide donating prostaglandin analogue to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also developing NCX 4251, a proprietary formulation of fluticasone, for the treatment of dry eye. Nicox generates sales of VYZULTA® in glaucoma, licensed exclusively to Bausch + Lomb worldwide, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies including Eyevance Pharmaceuticals, LLC in the US and Ocumension Therapeutics in China and most countries Southeast Asian markets.

Headquartered in Sophia Antipolis, France, Nicox is listed on Euronext Paris (compartment B: Mid Caps; ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information about Nicox, its products or its pipeline, please visit: www.nicox.com.

Analyst Reporting

Bryan, Garnier & Co Dylan Van Haaften Paris, France
Edison Investment Research Pooy…



Source story

More to explorer